2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 336

Lack of Uniform Diagnostic Criteria for Erosive OA: A Systematic Review
Abstract Number: 337

Construct Validity of the Doyle Index in the Outcome Domain of Joint Activity in Hand Osteoarthritis Patients
Abstract Number: 338

Smoking and Alcohol Use Are Associated with Structural and Inflammatory Hand Osteoarthritis Features in a Population Based Study
Abstract Number: 339

More Inflammatory Signs on Ultrasound, Severe Pain and Stiffness Are Associated with Erosive Than Non-Erosive Hand Osteoarthritis
Abstract Number: 340

Radiographic Assessment of Hand Osteoarthritis – the Role of Oblique View Images
Abstract Number: 341

Construct Validity of Four Hand Mobility Measures in Hand Osteoarthritis (HOA)
Abstract Number: 342

The Effect of Erosive Status on Systemic Inflammatory Biomarkers in Hand Osteoarthritis
Abstract Number: 343

Efficacy of Odanacatib in Postmenopausal Women with Osteoporosis: Subgroup Analyses of Data from the Phase 3 Long-Term Odanacatib Fracture Trial
Abstract Number: 344

Results of a Phase 2 Clinical Trial to Evaluate the Effects of Romosozumab in Japanese Women with Postmenopausal Osteoporosis
Abstract Number: 345

Relationship Between Total Hip BMD T-Score and Incidence of Nonvertebral Fracture with up to 8 Years of Denosumab Treatment
Abstract Number: 346

Autoantibodies to Osteoprotegerin Are Independently Associated with Low Hip Bone Mineral Density and Increased Fractures in Axial Spondyloarthritis
Abstract Number: 347

Safety Observations with 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab during the Pivotal 3-Year Trial and Subjects Who Crossed over to Denosumab during the Extension
Abstract Number: 348

Incidence Rate of Potential Osteonecrosis of the Jaw Among Women with Postmenopausal Osteoporosis Treated with Prolia or Bisphosphonates
Abstract Number: 349

Comparison Between the American Recommendations and the Japanese Guidelines for Glucocorticoid-Induced Osteoporosis in Japanese Patients with Rheumatoid Arthritis
Abstract Number: 350

Atypical Femur Fracture in Rheumatoid Arthritis Patients Treated with Bisphosphonates: A Nested Case-Control Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].